CDC Health Advisory: COVID-19 Rebound After Paxlovid Treatment
On May 24th, 2022, The Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory to update healthcare providers and the public on the potential for recurrence of COVID-19 or “COVID-19 rebound.”
COVID-19 rebound has been reported to occur between 2 and 8 days after initial recovery and is characterized by a recurrence of COVID-19 symptoms or a new positive viral test after having tested negative. The cause of a brief return of symptoms may be part of the natural history of SARS-CoV-2 infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status. There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected.
The CDC reports that Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19.
Please review the full CDC HAN Health Advisory.
View Therapeutic Order Status in HPOP
Providers can view the status of an order in HPOP by clicking on the order line under the Therapeutic Orders tab.
Once an order reaches a status of “Completed,” “On-Hold,” “Distributed,” or “Transmitted” there is nothing more a Provider needs to do.
-
Submitted - Request placed by a provider in HPOP.
-
Processing - Request is being reviewed by Texas DSHS.
-
Completed - Texas DSHS has completed the review and the order is waiting for the distributor to do a check of the account before accepting the order.
-
On Hold - Order completed, but the provider details did not include an AmerisourceBergen (ASD) Account listed in HPOP. ASD reviews these orders and updates the ASD Account number in HPOP for the provider if necessary. After entering a valid ASD Account number, the order shows as Distributed or Transmitted.
-
Distributed - Order completed and combined for the distributor to pick up.
-
Transmitted -The distributor downloaded the order.
-
Shipped - Order has been shipped by the distributor. Tracking information should be available. If a shipment is incorrect or missing, please contact C19Therapies@AmerisourceBergen.com.
-
Cancelled - A Texas DSHS user canceled the order.
Note: A created order request does NOT guarantee that an order will be distributed to the Provider. It must first be reviewed and approved by Texas DSHS.
Visit Check the status of a therapeutic order (oracle.com) for more information.
Shelf-life Extensions for COVID Therapeutics
Monoclonal Antibodies
Providers are strongly encouraged to maintain their supply of monoclonal antibodies under proper storage conditions even if the product is not currently authorized for administration. It is expected that these will be used again in the long-term. Providers should check the expiration dates with the manufacturer prior to removing any product from the cold chain.
Please see the various links for specific lot information:
Data supporting any expiration date extensions of Evusheld will be reviewed by the FDA for consideration. Do not discard Evusheld due to expiration until further notice, which should come in mid-summer.
Note: Doses discarded on site (compromised vial, unused diluted vials, etc.) should be recorded in the Wastage section in HPOP.
Paxlovid
Paxlovid Availability, Treatment Guidelines, and Locator Tools
As a reminder, Texas has Paxlovid (ritonavir-boosted nirmatrelvir), which is the first line treatment per the NIH Treatment Guidelines for High-Risk patients with symptomatic COVID-19 infection, stocked in pharmacies across the state of Texas.
Please use the HHS Therapeutics Locator to find the nearest pharmacy to your patient with Paxlovid (ritonavir-boosted nirmatrelvir) in stock. Patients can also access Federal Test to Treat Sites to receive testing and access to the prescription in the same location.
Additional clinical considerations for Paxlovid (ritonavir-boosted nirmatrelvir) can be reviewed in the NIH Treatment Guidelines section on Paxlovid (ritonavir-boosted nirmatrelvir).
To learn more about Paxlovid and other available therapeutic treatments, please read the 5/17/22 DSHS Communication shared with providers, or visit the DSHS Information for COVID-19 Therapeutics Providers webpage.
Learn About Paxlovid:
Drug Interaction Tools:
Coming Soon in HPOP: NPI Required
HPOP will require National Provider Identifiers (NPI) in the coming weeks. Texas DSHS will not be able to process the request without the NPI.
Get ready for the change by adding the NPI for your facility. Providers can now enter NPI under the “Provider Details” tab in HPOP.
HPOP Tip: Updating HPOP Users
An HPOP user can add additional contacts for their site.
- To the right of the Contacts heading, select the ADD (green box with a + sign)
- In the Add Contact dialog box, enter Email Address. Select
-
Enter First Name, Last Name, and Phone. You may add the information in the additional fields.
-
Toggle the Primary Contact button to activate or deactivate the contact as the primary contact. The white button toggles to the right and the box turns green when activated or to the left and gray when deactivated.
- Select the Therapeutic check box.
- Select Create..
- You may also remove a user from your account by opening the contact and selecting Delete Contact.
|
